Emerging Drugs for Hypogonadism

October 2006 in “ Expert Opinion on Emerging Drugs ”

Daniel L. Edelstein, Adrian S. Dobs, Shehzad Basaria

testosterone testosterone esters transdermal formulations testosterone undecanoate selective androgen receptor modulators SARMs 7α-methyl-19-nortestosterone aromatase inhibitors clomifene dihydrotestosterone human chorionic gonadotropin testosterone patches DHT hCG

Studysummary This review discusses trends in testosterone therapy use for male hypogonadism and reports no new clinical results, noting a shift towards more convenient and physiological treatments.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document reviewed emerging drugs for the treatment of hypogonadism as of 2006. It discussed various therapeutic options that were being developed to address the condition, which is characterized by low testosterone levels. The authors highlighted the potential benefits and mechanisms of action of these new drugs, as well as their clinical implications. The review emphasized the need for further research to establish the efficacy and safety of these treatments in larger populations, as the studies available at the time were limited in size and scope.

View this study on tandfonline.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, and EAU Recommendations

280 citations , May 2005 in “Andrology”

This document outlines recommendations from an international panel on testosterone therapy for aging men with late-onset hypogonadism, emphasizing the need for careful assessment and monitoring due to limited long-term safety data.

research Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators

129 citations , January 2004 in “Journal of medicinal chemistry”

This study synthesized nonsteroidal ligands as second-generation androgen receptor agonists and identified three compounds with significant anabolic activity and moderate to minimal androgenic activity in vivo.

research The Effects of Transdermal Dihydrotestosterone in the Aging Male: A Prospective, Randomized, Double-Blind Study

110 citations , April 2002 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

Prostate-Sparing Effects in Primates of the Potent Androgen 7α-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception

research Prostate-Sparing Effects in Primates of the Potent Androgen 7α-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception

14 citations , December 1998 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.